These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35427802)

  • 1. The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.
    Reis-Barbosa PH; Marcondes-de-Castro IA; Marinho TS; Aguila MB; Mandarim-de-Lacerda CA
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101922. PubMed ID: 35427802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist.
    Pontes-da-Silva RM; de Souza Marinho T; de Macedo Cardoso LE; Mandarim-de-Lacerda CA; Aguila MB
    Int J Obes (Lond); 2022 Jan; 46(1):21-29. PubMed ID: 34465857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice.
    Martins FF; Marinho TS; Cardoso LEM; Barbosa-da-Silva S; Souza-Mello V; Aguila MB; Mandarim-de-Lacerda CA
    Cell Biochem Funct; 2022 Dec; 40(8):903-913. PubMed ID: 36169111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotadutide effect in liver and adipose tissue in obese mice.
    Marcondes-de-Castro IA; Oliveira TF; Spezani R; Marinho TS; Cardoso LEM; Aguila MB; Mandarim-de-Lacerda CA
    J Mol Endocrinol; 2023 Apr; 70(3):. PubMed ID: 36753306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
    He Q; Sha S; Sun L; Zhang J; Dong M
    Biochem Biophys Res Commun; 2016 Aug; 476(4):196-203. PubMed ID: 27208776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice.
    Cardoso LEM; Marinho TS; Martins FF; Aguila MB; Mandarim-de-Lacerda CA
    Life Sci; 2023 Apr; 319():121502. PubMed ID: 36796719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic islet cells disarray, apoptosis, and proliferation in obese mice. The role of Semaglutide treatment.
    Marinho TS; Martins FF; Cardoso LEM; Aguila MB; Mandarim-de-Lacerda CA
    Biochimie; 2022 Feb; 193():126-136. PubMed ID: 34742857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
    Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Anti-Obesity and Anti-Steatotic Effects of Chrysin in a Rat Model of Obesity Mediated through Modulating the Hepatic AMPK/mTOR/lipogenesis Pathways.
    Oriquat G; Masoud IM; Kamel MA; Aboudeya HM; Bakir MB; Shaker SA
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-frequency electroacupuncture improves disordered hepatic energy metabolism in insulin-resistant Zucker diabetic fatty rats via the AMPK/mTORC1/p70S6K signaling pathway.
    Liu XX; Zhang LZ; Zhang HH; Lai LF; Wang YQ; Sun J; Xu NG; Li ZX
    Acupunct Med; 2022 Aug; 40(4):360-368. PubMed ID: 35034504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition.
    Huang H; Lee SH; Sousa-Lima I; Kim SS; Hwang WM; Dagon Y; Yang WM; Cho S; Kang MC; Seo JA; Shibata M; Cho H; Belew GD; Bhin J; Desai BN; Ryu MJ; Shong M; Li P; Meng H; Chung BH; Hwang D; Kim MS; Park KS; Macedo MP; White M; Jones J; Kim YB
    J Clin Invest; 2018 Dec; 128(12):5335-5350. PubMed ID: 30226474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression.
    Marcondes-de-Castro IA; Reis-Barbosa PH; Marinho TS; Aguila MB; Mandarim-de-Lacerda CA
    J Gastroenterol Hepatol; 2023 Nov; 38(11):1868-1876. PubMed ID: 37438882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.
    Ben-Shlomo S; Zvibel I; Shnell M; Shlomai A; Chepurko E; Halpern Z; Barzilai N; Oren R; Fishman S
    J Hepatol; 2011 Jun; 54(6):1214-23. PubMed ID: 21145820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
    McGlone ER; Hope DCD; Davies I; Dore M; Goldin R; Jones B; Liu Z; Li JV; Vorkas PA; Khoo B; Carling D; Minnion J; Bloom SR; Tan TM
    Biomed Pharmacother; 2024 Jul; 176():116888. PubMed ID: 38861859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPK activation prevents excess nutrient-induced hepatic lipid accumulation by inhibiting mTORC1 signaling and endoplasmic reticulum stress response.
    Li H; Min Q; Ouyang C; Lee J; He C; Zou MH; Xie Z
    Biochim Biophys Acta; 2014 Sep; 1842(9):1844-54. PubMed ID: 25016145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice.
    Lee J; Hong SW; Chae SW; Kim DH; Choi JH; Bae JC; Park SE; Rhee EJ; Park CY; Oh KW; Park SW; Kim SW; Lee WY
    PLoS One; 2012; 7(2):e31394. PubMed ID: 22363635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway.
    Yang S; Lin C; Zhuo X; Wang J; Rao S; Xu W; Cheng Y; Yang L
    Am J Physiol Endocrinol Metab; 2020 Dec; 319(6):E1019-E1030. PubMed ID: 32985256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of the mTORC1/STAT3/Notch1 pathway by activated AMPK prevents hepatic insulin resistance induced by excess amino acids.
    Li H; Lee J; He C; Zou MH; Xie Z
    Am J Physiol Endocrinol Metab; 2014 Jan; 306(2):E197-209. PubMed ID: 24302004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Takeda G Protein-Coupled Receptor 5-Mechanistic Target of Rapamycin Complex 1 Signaling Contributes to the Increment of Glucagon-Like Peptide-1 Production after Roux-en-Y Gastric Bypass.
    Zhai H; Li Z; Peng M; Huang Z; Qin T; Chen L; Li H; Zhang H; Zhang W; Xu G
    EBioMedicine; 2018 Jun; 32():201-214. PubMed ID: 29859856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.